Fragment-based screening by protein crystallography: Successes and pitfalls

International Journal of Molecular Sciences

Volumn 13, Issue 10, 2012, Pages 12857-12879

  Chilingaryan, Zorik ^a   Yin, Zhou ^a   Oakley, Aaron J ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Crystallography; Drug design; Fragment based screening; Synchrotron radiation; X ray

Indexed keywords

2 AMINO 3 [[2 (BENZYLOXY) 5 (1H INDOL 6 YL)BENZYL]AMINO]PYRIDINE; 2 AMINO 3 [[3 (5 METHOXYPYRIDIN 3 YL)BENZYL]AMINO]PYRIDINE; 2 AMINO 3 [[3 (5 PROPYLOXYPYRIDIN 3 YL)BENZYL]AMINO]PYRIDINE; 2 AMINO 3 [[3 (PYRIDIN 3 YL)BENZYL]AMINO]PYRIDINE; 2 AMINO 6 PHENYLPYRIDINE; 2 AMINO 6 [2 (3' METHOXY [1,1' BIPHENYL] 3 YL)ETHYL]PYRIDINE; 2 [2 (1H INDOL 6 YL)ETHYL] 6 AMINOPYRIDINE; 3 [3 (1H INDOL 6 YL)BENZYL] 2 AMINOPYRIDINE; 3 [[5 (1H INDOL 6 YL) 2 (PYRIDIN 2 YLMETHOXY)BENZYL]AMINO] 2 AMINOPYRIDINE; BETA SECRETASE; BETA SECRETASE INHIBITOR; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; METHYLTRANSFERASE; N METHYLTRANSFERASE; PENTOXIFYLLINE; PHENYLETHANOLAMINE; PHOSPHODIESTERASE 4A; PHOSPHODIESTERASE IV; UNCLASSIFIED DRUG; DRUG; PHENYLETHANOLAMINE N METHYLTRANSFERASE; PROTEIN; SECRETASE;

COMPUTER PROGRAM; DRUG STRUCTURE; MOLECULAR LIBRARY; PROTEIN TARGETING; REVIEW; ROBOTICS; SCREENING TEST; SYNCHROTRON RADIATION; X RAY ANALYSIS; X RAY CRYSTALLOGRAPHY; BINDING SITE; CHEMISTRY; DRUG DESIGN; METABOLISM; PROTEIN TERTIARY STRUCTURE;

AMYLOID PRECURSOR PROTEIN SECRETASES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; PHARMACEUTICAL PREPARATIONS; PHENYLETHANOLAMINE N-METHYLTRANSFERASE; PROTEIN STRUCTURE, TERTIARY; PROTEINS;

EID: 84867806564     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131012857     Document Type: Review

References (75)

1. Larsson, A.; Jansson, A.; Aberg, A.; Nordlund, P. Efficiency of hit generation and structural characterization in fragment-based ligand discovery. Curr. Opin. Chem. Biol. 2012, 15, 482-488.
2. Davies, T.G.; Tickle, I.J. Fragment screening using X-ray crystallography. Top. Curr. Chem. 2012, 317, 33-59.
3. Fitzpatrick, P.A.; Steinmetz, A.C.; Ringe, D.; Klibanov, A.M. Enzyme crystal structure in a neat organic solvent. Proc. Natl. Acad. Sci. USA 1993, 90, 8653-8657.
4. English, A.C.; Done, S.H.; Caves, L.S.; Groom, C.R.; Hubbard, R.E. Locating interaction sites on proteins: The crystal structure of thermolysin soaked in 2% to 100% isopropanol. Proteins 1999, 37, 628-640.
5. Shuker, S.B.; Hajduk, P.J.; Meadows, R.P.; Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274, 1531-1534.
6. Stout, T.J.; Sage, C.R.; Stroud, R.M. The additivity of substrate fragments in enzyme-ligand binding. Structure 1998, 6, 839-848.
7. Lesuisse, D.; Lange, G.; Deprez, P.; Benard, D.; Schoot, B.; Delettre, G.; Marquette, J.P.; Broto, P.; Jean-Baptiste, V.; Bichet, P.; et al. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: Application to the discovery of nanomolar inhibitors of Src SH2. J. Med. Chem. 2002, 45, 2379-2387.
8. Maly, D.J.; Choong, I.C.; Ellman, J.A. Combinatorial target-guided ligand assembly: Identification of potent subtype-selective c-Src inhibitors. Proc. Natl. Acad. Sci. USA 2000, 97, 2419-2424.
9. Boehm, H.J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 2000, 43, 2664-2674.
10. Fejzo, J.; Lepre, C.A.; Peng, J.W.; Bemis, G.W.; Ajay; Murcko, M.A.; Moore, J.M. The SHAPES strategy: An NMR-based approach for lead generation in drug discovery. Chem. Biol. 1999, 6, 755-769.
11. Liebeschuetz, J.W.; Jones, S.D.; Morgan, P.J.; Murray, C.W.; Rimmer, A.D.; Roscoe, J.M.; Waszkowycz, B.; Welsh, P.M.; Wylie, W.A.; Young, S.C.; et al. PRO_SELECT: Combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors. J. Med. Chem. 2002, 45, 1221-1232.
12. Wyss, D.F.; Wang, Y.S.; Eaton, H.L.; Strickland, C.; Voigt, J.H.; Zhu, Z.; Stamford, A.W. Combining NMR and X-ray crystallography in fragment-based drug discovery: Discovery of highly potent and selective BACE-1 inhibitors. Top. Curr. Chem. 2012, 317, 83-114.
13. Hann, M.M.; Leach, A.R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
14. Murray, C.W.; Verdonk, M.L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J. Comput. Aided. Mol. Des. 2002, 16, 741-753.
15. Hopkins, A.L.; Groom, C.R.; Alex, A. Ligand efficiency: A useful metric for lead selection. Drug Discov. Today 2004, 9, 430-431.
16. Carr, R.A.E.; Congreve, M.; Murray, C.W.; Rees, D.C. Fragment-based lead discovery: Leads by design. Drug Discov. Today 2005, 10, 987-992.
17. Ciulli, A.; Abell, C. Fragment-based approaches to enzyme inhibition. Curr. Opin. Biotechnol. 2007, 18, 489-496.
18. Kranz, J.K.; Schalk-Hihi, C. Protein thermal shifts to identify low molecular weight fragments. Methods Enzymol. 2011, 493, 277-298.
19. Giannetti, A.M. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. Methods Enzymol. 2011, 493, 169-218.
20. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
21. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A 'rule of three' for fragment-based lead discovery? Drug Discov. Today 2003, 8, 876-877.
22. Hung, A.W.; Ramek, A.; Wang, Y.; Kaya, T.; Wilson, J.A.; Clemons, P.A.; Young, D.W. Route to three-dimensional fragments using diversity-oriented synthesis. Proc. Natl. Acad. Sci. USA 2011, 108, 6799-6804.
23. Bohacek, R.S.; McMartin, C.; Guida, W.C. The art and practice of structure-based drug design: A molecular modeling perspective. Med. Res. Rev. 1996, 16, 3-50.
24. Drew, K.L.M.; Baiman, H.; Khwaounjoo, P.; Yu, B.; Reynisson, J. Size estimation of chemical space: How big is it? J. Pharm. Pharmacol. 2012, 64, 490-495.
25. Fink, T.; Reymond, J.L. Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: Assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J. Chem. Inf. Model. 2007, 47, 342-353.
26. Weininger, D. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J. Chem. Inf. Comput. Sci. 1988, 28, 31-36.
27. Kong, F.; Yuan, L.; Zheng, Y.F.; Chen, W. Automatic liquid handling for life science: A critical review of the current state of the art. J. Lab. Autom. 2012, 17, 169-185.
28. Chayen, N.E. Optimization Techniques for Automation and High Throughput. In Methods in Molecular Biology; Doublié, S., Ed.; Humana Press: Totowa, NJ, USA, 2007; Volume 363, pp. 175-190.
29. Grueninger-Leitch, F.; D'Arcy, A.; D'Arcy, B.; Chene, C. Deglycosylation of proteins for crystallization using recombinant fusion protein glycosidases. Protein Sci. 1996, 5, 2617-2622.
30. Dong, A.; Xu, X.; Edwards, A.M.; Chang, C.; Chruszcz, M.; Cuff, M.; Cymborowski, M.; Di Leo, R.; Egorova, O.; Evdokimova, E.; et al. In situ proteolysis for protein crystallization and structure determination. Nat. Methods 2007, 4, 1019-1021.
31. Derewenda, Z.S. Application of protein engineering to enhance crystallizability and improve crystal properties. Acta Crystallogr. D 2010, 66, 604-615.
32. Jenkins, T.M.; Hickman, A.B.; Dyda, F.; Ghirlando, R.; Davies, D.R.; Craigie, R. Catalytic domain of human immunodeficiency virus type 1 integrase: Identification of a soluble mutant by systematic replacement of hydrophobic residues. Proc. Natl. Acad. Sci. USA 1995, 92, 6057-6061.
33. Dyda, F.; Hickman, A.B.; Jenkins, T.M.; Engelman, A.; Craigie, R.; Davies, D.R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994, 266, 1981-1986.
34. H., Brock, J., Liu, D., Board, P.G., Oakley, A.J. Structural insights into the dehydroascorbate reductase activity of human omega-class glutathione transferases. J. Mol. Biol. 2012, 420, 190-203.
35. Patel, S.B.; Cameron, P.M.; Frantz-Wattley, B.; O'Neill, E.; Becker, J.W.; Scapin, G. Lattice stabilization and enhanced diffraction in human p38α crystals by protein engineering. Biochim. Biophys. Acta 2004, 1696, 67-73.
36. Badger, J. Crystallographic fragment screening. Methods Mol. Biol. 2012, 841, 161-177.
37. Wasserman, S.R.; Koss, J.W.; Sojitra, S.T.; Morisco, L.L.; Burley, S.K. Rapid-access, high-throughput synchrotron crystallography for drug discovery. Trends Pharmacol. Sci. 2012, 33, 261-267.
38. Hülsen, G.; Broennimann, C.; Eikenberry, E.F.; Wagner, A. Protein crystallography with a novel large-area pixel detector. J. Appl. Crystallogr. 2006, 39, 550-557.
39. De Sanctis, D.; Beteva, A.; Caserotto, H.; Dobias, F.; Gabadinho, J.; Giraud, T.; Gobbo, A.; Guijarro, M.; Lentini, M.; Lavault, B.; et al. ID29: A high-intensity highly automated ESRF beamline for macromolecular crystallography experiments exploiting anomalous scattering. J. Synchrotron. Radiat. 2012, 19, 455-461.
40. Smith, C.A.; Cohen, A.E. The stanford automated mounter: Enabling high-throughput protein crystal screening at SSRL. J. Lab. Autom. 2008, 13, 335-343.
41. McPhillips, T.M.; McPhillips, S.E.; Chiu, H.J.; Cohen, A.E.; Deacon, A.M.; Ellis, P.J.; Garman, E.; Gonzalez, A.; Sauter, N.K.; Phizackerley, R.P.; et al. Blu-ice and the distributed control system: Software for data acquisition and instrument control at macromolecular crystallography beamlines. J. Synchrotron. Radiat. 2002, 9, 401-406.
42. Beteva, A.; Cipriani, F.; Cusack, S.; Delageniere, S.; Gabadinho, J.; Gordon, E.J.; Guijarro, M.; Hall, D.R.; Larsen, S.; Launer, L.; et al. High-throughput sample handling and data collection at synchrotrons: Embedding the ESRF into the high-throughput gene-to-structure pipeline. Acta Crystallogr. D 2006, 62, 1162-1169.
43. Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D 2004, 60, 2126-2132.
44. Terwilliger, T.C.; Adams, P.D.; Moriarty, N.W.; Cohn, J.D. Ligand identification using electron-density map correlations. Acta Crystallogr. D 2007, 63, 101-107.
45. Evrard, G.X.; Langer, G.G.; Perrakis, A.; Lamzin, V.S. Assessment of automatic ligand building in ARP/wARP. Acta Crystallogr. D 2007, 63, 108-117.
46. Mooij, W.T.; Hartshorn, M.J.; Tickle, I.J.; Sharff, A.J.; Verdonk, M.L.; Jhoti, H. Automated protein-ligand crystallography for structure-based drug design. ChemMedChem 2006, 1, 827-838.
47. Jones, T.A.; Kjeldgaard, M. Electron-density map interpretation. Methods Enzymol. 1997, 277, 173-208.
48. Davis, A.M.; Teague, S.J.; Kleywegt, G.J. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew. Chem. Int. Ed. Engl. 2003, 42, 2718-2736.
49. Davis, A.M.; St-Gallay, S.A.; Kleywegt, G.J. Limitations and lessons in the use of X-ray structural information in drug design. Drug Discov. Today 2008, 13, 831-841.
50. Malde, A.K.; Mark, A.E. Challenges in the determination of the binding modes of non-standard ligands in X-ray crystal complexes. J. Comput. Aided Mol. Des. 2011, 25, 1-12.
51. Kleywegt, G.J.; Henrick, K.; Dodson, E.J.; van Aalten, D.M. Pound-wise but penny-foolish: How well do micromolecules fare in macromolecular refinement? Structure 2003, 11, 1051-1059.
52. Ward, R.A.; Brassington, C.; Breeze, A.L.; Caputo, A.; Critchlow, S.; Davies, G.; Goodwin, L.; Hassall, G.; Greenwood, R.; Holdgate, G.A.; et al. Design and synthesis of novel lactate dehydrogenase a inhibitors by fragment-based lead generation. J. Med. Chem. 2012, 55, 3285-3306.
53. Yang, H.; Yang, M.; Ding, Y.; Liu, Y.; Lou, Z.; Zhou, Z.; Sun, L.; Mo, L.; Ye, S.; Pang, H.; et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. USA 2003, 100, 13190-13195.
54. Murray, C.W.; Callaghan, O.; Chessari, G.; Cleasby, A.; Congreve, M.; Frederickson, M.; Hartshorn, M.J.; McMenamin, R.; Patel, S.; Wallis, N. Application of fragment screening by X-ray crystallography to beta-secretase. J. Med. Chem. 2007, 50, 1116-1123.
55. Congreve, M.; Aharony, D.; Albert, J.; Callaghan, O.; Campbell, J.; Carr, R.A.E.; Chessari, G.; Cowan, S.; Edwards, P.D.; Frederickson, M.; et al. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. J. Med. Chem. 2007, 50, 1124-1132.
56. Nair, P.C.; Malde, A.K.; Drinkwater, N.; Mark, A.E. Missing fragments: Detecting cooperative binding in fragment-based drug design. ACS Med. Chem. Lett. 2012, 3, 322-326.
57. Recht, M.I.; Sridhar, V.; Badger, J.; Hernandez, L.; Chie-Leon, B.; Nienaber, V.; Torres, F.E. Fragment-based screening for inhibitors of PDE4A using enthalpy arrays and X-ray crystallography. J. Biomol. Screen. 2012, 17, 469-480.
58. Murray, C.W.; Carr, M.G.; Callaghan, O.; Chessari, G.; Congreve, M.; Cowan, S.; Coyle, J.E.; Downham, R.; Figueroa, E.; Frederickson, M.; et al. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J. Med. Chem. 2010, 53, 5942-5955.
59. Woodhead, A.J.; Angove, H.; Carr, M.G.; Chessari, G.; Congreve, M.; Coyle, J.E.; Cosme, J.; Graham, B.; Day, P.J.; Downham, R.; et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J. Med. Chem. 2010, 53, 5956-5969.
60. Chung, C.W.; Dean, A.W.; Woolven, J.M.; Bamborough, P. Fragment-based discovery of bromodomain inhibitors part 1: Inhibitor binding modes and implications for lead discovery. J. Med. Chem. 2012, 55, 576-586.
61. Bamborough, P.; Diallo, H.; Goodacre, J.D.; Gordon, L.; Lewis, A.; Seal, J.T.; Wilson, D.M.; Woodrow, M.D.; Chung, C.-W. Fragment-based discovery of bromodomain inhibitors part 2: Optimization of phenylisoxazole sulfonamides. J. Med. Chem. 2011, 55, 587-596.
62. Nichols, D.A.; Jaishankar, P.; Larson, W.; Smith, E.; Liu, G.; Beyrouthy, R.; Bonnet, R.; Renslo, A.R.; Chen, Y. Structure-based design of potent and ligand-efficient inhibitors of CTX-M Class A β-lactamase. J. Med. Chem. 2012, 55, 2163-2172.
63. Congreve, M.; Andrews, S.P.; Doré, A.S.; Hollenstein, K.; Hurrell, E.; Langmead, C.J.; Mason, J.S.; Ng, I.W.; Tehan, B.; Zhukov, A.; et al. Discovery of 1,2,4-triazine derivatives as adenosine A2A antagonists using structure based drug design. J. Med. Chem. 2012, 55, 1898-1903.
64. Certal, V.; Halley, F.; Virone-Oddos, A.; Delorme, C.; Karlsson, A.; Rak, A.; Thompson, F.; Filoche-Rommé, B.; El-Ahmad, Y.; Carry, J.-C.; et al. Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers. J. Med. Chem. 2012, 55, 4788-4805.
65. Gitto, R.; Damiano, F.M.; Mader, P.; de Luca, L.; Ferro, S.; Supuran, C.T.; Vullo, D.; Brynda, J.; Řezáčová, P.; Chimirri, A. Synthesis, structure-activity relationship studies, and X-ray crystallographic analysis of arylsulfonamides as potent carbonic anhydrase inhibitors. J. Med. Chem. 2012, 55, 3891-3899.
66. Good, A.C.; Liu, J.; Hirth, B.; Asmussen, G.; Xiang, Y.; Biemann, H.-P.; Bishop, K.A.; Fremgen, T.; Fitzgerald, M.; Gladysheva, T.; et al. Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug design. J. Med. Chem. 2012, 55, 2641-2648.
67. Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C.W.; Yon, J. Apo and inhibitor complex structures of BACE (β-secretase). J. Mol. Biol. 2004, 343, 407-416.
68. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
69. Torres, F.E.; Kuhn, P.; de Bruyker, D.; Bell, A.G.; Wolkin, M.V.; Peeters, E.; Williamson, J.R.; Anderson, G.B.; Schmitz, G.P.; Recht, M.I.; et al. Enthalpy arrays. Proc. Natl. Acad. Sci. USA 2004, 101, 9517-9522.
70. Drinkwater, N.; Vu, H.; Lovell, K.M.; Criscione, K.R.; Collins, B.M.; Prisinzano, T.E.; Poulsen, S.A.; McLeish, M.J.; Grunewald, G.L.; Martin, J.L. Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors. Biochem. J. 2010, 431, 51-61.
71. Pearl, L.H.; Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75, 271-294.
72. Mahalingam, D.; Swords, R.; Carew, J.S.; Nawrocki, S.T.; Bhalla, K.; Giles, F.J. Targeting HSP90 for cancer therapy. Br. J. Cancer 2009, 100, 1523-1529.
73. Cheung, C.H.; Chen, H.H.; Cheng, L.T.; Lyu, K.W.; Kanwar, J.R.; Chang, J.Y. Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Mol. Cancer 2010, 9, 77.
74. Lu, X.; Xiao, L.; Wang, L.; Ruden, D.M. Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem. Pharmacol. 2012, 83, 995-1004.
75. Neckers, L.; Workman, P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin. Cancer Res. 2012, 18, 64-76.